Ontada

READ: Ontada's VP of Biostatistics Zhaohui Su discusses research presented at the 2024 ISPOR—The Professional Society for Health Economics and Outcomes Research Annual Meeting, "Development and Application of a Framework for Addressing New Challenges of Missing Data in Real-World Research." Learn more: https://lnkd.in/g4qhtCF4 #Ontada #ISPOR #ISPOR2024 #Clinical #Medical #Healthcare #Oncology

On a recent episode of the Oncology Overdrive podcast, host Shikha Jain, MD, FACP spoke with David Cosgrove, MD, medical director of Compass Oncology about the applications of real-world data, diversity in clinical trials, and more. Listen to the full episode: https://lnkd.in/e-sWct8W #Ontada #Oncology #Podcast #Cancer #Medicine #Medical #Healthcare

What are the actual clinical outcomes when patients receive guideline treatments? In this study, our team examined real-world clinical outcomes for patients with BRAF-mutant advanced/metastatic melanoma. Read the results: https://lnkd.in/g_Y7Dr3W #RWD #RWE #Melanoma

While recommendations for standard-of-care first-line treatments exist, patients do not always receive guideline-based care. In this study presented at #ASCO24, we examined real-world treatment patterns and overall survival in patients with locally advanced/metastatic urothelial carcinoma. Here's what we found: https://lnkd.in/gFQCMqzh #Avelumab #Monotherapy #Chermotherapy

READ: Ontada's recent research presented at ISPOR 2024 highlights the potential for AI and NLP to aid recruitment in clinical trials. Avi R. presented the findings, and Jess Paulus, ScD, Epidemiology, spoke about them with AJMC - The American Journal of Managed Care. Read more here: https://lnkd.in/gAfb5VjZ #AI #NLP #ClinicalTrials #RWD

Last month, Texas Oncology and DeepScribe announced a collaboration to reduce administrative burden for providers using DeepScribe's AI solutions. To make the scribing process as seamless as possible, DeepScribe has integrated its AI documentation into Ontada's EHR, iKnowMed. "Working with DeepScribe aligns perfectly with our mission to advance cancer care for all Texans," said Steve Paulson, M.D., president and CEO of Texas Oncology. "This innovative technology not only allows our clinicians to reduce time spent on documentation by significant hours each day, but also strengthens our ability to deliver better care.” Together, The US Oncology Network and Ontada create innovative solutions for practices and providers, attracting collaboration with some of the most impactful organizations in oncology and helping liberate physicians from their keyboards so they can spend more time with patients. Learn more: https://lnkd.in/grJsUJBc #AI #CommunityOncology #Innovation #CancerCare

In this retrospective cohort study, our team used structured and chart review data to assess biomarker characteristics and clinical outcomes among pre-treated non-MSI-H/dMMR metastatic colorectal cancer (mCRC) patients in community oncology practices. Read the outcome: https://lnkd.in/gJkM9BQg #CommunityOncology #mCRC #RWD

Honored to discuss Ontada's recent study that explored fit-for-purpose approaches for capture of real-world mortality data. Proud to be part of a team driving innovation in oncology research!

Definitive chemoradiotherapy (dCRT) is the current recommended treatment for patients with early-stage esophageal/gastroesophageal junction cancer (EC/GEJC). In this recent research, our team examined patient characteristics, current treatment patterns, and outcomes with dCRT regimens. See the results: https://lnkd.in/gn_uhzRs #dCRT #Chemoradiotherapy #CommunityOncology

At this year's ISPOR annual meeting, our team presented research examining the completeness of different real-world data (RWD) sources in recording mortality/vitality and their appropriateness for research. Kat Aguilar, MPH, Director of Real-World Research at Ontada, recently spoke to AJMC - The American Journal of Managed Care about our research. Read it here: https://lnkd.in/g74mWtgg #ISPOR #RWD #FitForPurposeData